US Patent Issued to Eisai R&D Management on March 3 for "Eribulin antibody-drug conjugates and methods of use" (Pennsylvania Inventors)

ALEXANDRIA, Va., March 3 -- United States Patent no. 12,564,641, issued on March 3, was assigned to Eisai R&D Management Co. Ltd. (Tokyo).

"Eribulin antibody-drug conjugates and methods of use" was invented by Earl F. Albone (Collegeville, Pa.) and Jared Spidel (Downingtown, Pa.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates such as those comprising eribulin) thereof that bind to mesothelin are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the compositions provided herein."

The patent was filed on Dec. 23, 2022, under Application No. 18/146,246.

*...